Literature DB >> 3964626

Delayed-onset chloroquine retinopathy.

M Ehrenfeld, R Nesher, S Merin.   

Abstract

Delayed-onset chloroquine retinopathy was diagnosed in a patient seven years after cessation of treatment by a total dose of 730 g of chloroquine for rheumatoid arthritis. Visual functions continued to deteriorate after the diagnosis. Periodic examinations by ophthalmoscopy and by functional tests such as EOG and visual fields should be continued in patients at risk of delayed-onset chloroquine retinopathy after discontinuance of the drug.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3964626      PMCID： PMC1040997          DOI： 10.1136/bjo.70.4.281

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN： 0007-1161            Impact factor:   4.638


  14 in total

1.  THE OCULAR DEPOSITION OF CHLOROQUINE.

Authors:  H BERNSTEIN; N ZVAIFLER; M RUBIN; A M MANSOUR
Journal:  Invest Ophthalmol       Date:  1963-08

2.  Chloroquine retinopathy; a report of eight cases with ERG and dark-adaptation findings.

Authors:  E OKUN; P GOURAS; H BERNSTEIN; L VON SALLMANN
Journal:  Arch Ophthalmol       Date:  1963-01

3.  Retinopathy following chloroquine therapy.

Authors:  H E HOBBS; A SORSBY; A FREEDMAN
Journal:  Lancet       Date:  1959-10-03       Impact factor: 79.321

4.  The ocular complications of chloroquine therapy.

Authors:  H E HOBBS; C D CALNAN
Journal:  Lancet       Date:  1958-06-07       Impact factor: 79.321

5.  Ocular toxicity of antimalarial drugs. Long-term follow-up.

Authors:  R E Carr; P Henkind; N Rothfield; I M Siegel
Journal:  Am J Ophthalmol       Date:  1968-10       Impact factor: 5.258

Review 6.  Chloroquine ocular toxicity.

Authors:  H N Bernstein
Journal:  Surv Ophthalmol       Date:  1967-10       Impact factor: 6.048

7.  Ocular damage in chloroquine therapy.

Authors:  U Nylander
Journal:  Acta Ophthalmol (Copenh)       Date:  1966

8.  Delayed onset of chloroquine retinopathy.

Authors:  R P Burns
Journal:  N Engl J Med       Date:  1966-09-29       Impact factor: 91.245

9.  Delayed onset of chloroquine retinopathy.

Authors:  H Reed; W Karlinsky
Journal:  Can Med Assoc J       Date:  1967-12-02       Impact factor: 8.262

10.  Antimalarial drugs for rheumatoid arthritis.

Authors:  A H Mackenzie
Journal:  Am J Med       Date:  1983-12-30       Impact factor: 4.965
View more
  8 in total

1.  Ophthaproblem. Chloroquine or hydroxychloroquine retinopathy.

Authors:  Wei Liu; Sanjay Sharma
Journal:  Can Fam Physician       Date:  2005-05       Impact factor: 3.275

2.  Threshold Amsler grid as a screening tool for asymptomatic patients on hydroxychloroquine therapy.

Authors:  A Almony; S Garg; R K Peters; R Mamet; J Tsong; B Shibuya; R Kitridou; A A Sadun
Journal:  Br J Ophthalmol       Date:  2005-05       Impact factor: 4.638

3.  Delayed progression of bull's eye maculopathy.

Authors:  Sunila Jain; Neel Gautam Jain
Journal:  BMJ Case Rep       Date:  2017-06-08

4.  Is thioridazine retinopathy progressive? Relationship of pigmentary changes to visual function.

Authors:  M F Marmor
Journal:  Br J Ophthalmol       Date:  1990-12       Impact factor: 4.638

5.  Improving the risk-benefit relationship and informed consent for patients treated with hydroxychloroquine.

Authors:  Allan J Flach
Journal:  Trans Am Ophthalmol Soc       Date:  2007

Review 6.  Clinically important ocular reactions to systemic drug therapy.

Authors:  I G Rennie
Journal:  Drug Saf       Date:  1993-09       Impact factor: 5.606

7.  Relative sensitivity and specificity of 10-2 visual fields, multifocal electroretinography, and spectral domain optical coherence tomography in detecting hydroxychloroquine and chloroquine retinopathy.

Authors:  David J Browning; Chong Lee
Journal:  Clin Ophthalmol       Date:  2014-07-25

8.  Quantitative Fundus Autofluorescence in Systemic Chloroquine/Hydroxychloroquine Therapy.

Authors:  Clara Reichel; Andreas Berlin; Victoria Radun; Ioana-Sandra Tarau; Jost Hillenkamp; Nikolai Kleefeldt; Kenneth R Sloan; Thomas Ach
Journal:  Transl Vis Sci Technol       Date:  2020-08-28       Impact factor: 3.283
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.